Monoclonal antibody as therapy for malignant lymphomas |
| |
| Authors: | Coiffier Bertrand |
| |
| Institution: | Service d'Hématologie, Hospices Civils de Lyon et Université Claude-Bernard, Lyon-1, CH Lyon-Sud, 69495 Pierre-Bénite, France. bertrand.coiffier@chu-lyon.fr |
| |
| Abstract: | Rituximab was the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies have demonstrated its activity in follicular lymphoma, mantle-cell lymphoma, and diffuse large B-cell lymphoma in untreated or relapsing patients. Because of its high activity and low toxicity ratio, rituximab has transformed the outcome of patients with B-cell lymphoma. A combination of rituximab plus chemotherapy, R-CHOP, has the highest efficacy ever described with any chemotherapy in diffuse large B-cell lymphoma and follicular lymphoma. The role of radio-labelled antibodies is still to be defined. |
| |
| Keywords: | Rituximab R-CHOP Follicular lymphoma Diffuse large B-cell lymphoma Radio-labelled antibodies Monoclonal antibodies Rituximab R-CHOP Lymphome folliculaire Lymphome à grandes cellules B Anticorps marqués radioactivement Anticorps monoclonaux |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
